Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Bevacizumab for Severe Retinopathy of Prematurity
NCT02390531Phase 1Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Apr 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, double-blind trial of bevacizumab in retinopathy of prematurity (ROP) (8 arms), sponsored by Jaeb Center for Health Research. Primary endpoint: Number of Participants With Successful Treatment of ROP. Started Apr 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02390531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390531.